Our Team

Inspired to be exceptional

With decades of experience developing new therapies and building companies, we aspire to excellence through collaboration with experts and family organizations who understand the problems faced every day by children and adults with serious neuropsychiatric conditions.

Leadership

Mark A. Tepper, Ph.D.

President & CEO

Randall Marshall, M.D.

Chief Medical Officer

James W. Larrick, M.D., Ph.D.

Chief Scientific Officer

Marc Bailie, PhD

Head of Toxicology

Catherine Moncad

Head of Regulatory Services (TMC)

Greg Coulter, PhD

Head of CMC

Joanne Emmett

Head of Clinical Operations

Scientific Advisors

Stuart Lipton, M.D., Ph.D. (Scientific Founder)
Professor, Scripps Research Institute and UC San Diego, La Jolla

• Harvard-trained board-certified neurologist, on Harvard faculty for 25 yrs - KOL
• Scientific Founder of EuMentis Therapeutics & Adamas
• Developer/Patent Holder of memantine (Namenda®, NamendaXR®, Namzaric®)

Jeffrey L. Neul, M.D., Ph.D.
Professor, Vanderbilt School of Medicine, Nashville, TN

• Expert in neurodevelopmental disorders/ASD including Rett Syndrome

Stephen Traynelis, Ph.D.
Professor, Dept of Pharmacology, Emory School of Medicine, Atlanta, GA

• Expert in Neurobiology & NMDAR Structure/Function & Pharmacology

Gagan Joshi, M.D.
Associate Professor, Psychiatry, Harvard Medical School; Director, Autism Spectrum Disorder Program, Mass General Hospital

• Expert in ASD and Pediatric Psychopharmacology

Donald Gilbert, MD
Professor, University of Cincinnati, Cincinnati Children’s Hospital

• Expert on neurobiology, research and treatment of Tourette Syndrome and ADHD
• Specialist in Pediatric Movement Disorders

Keith A. Coffman, MD
Associate Professor, Children’s Mercy Hospital

• Expert on neurobiology and treatment of Tourette Syndrome
• Children’s Mercy Tourette Center of Excellence
• Tourette Association of America Medical Advisory Board